title: Is low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study.
authors.affiliation: Division of Hematology/Medical Oncology, Department of Medicine, Oregon Health Sciences University, Portland, Oregon.|Division of Laboratory Medicine, Department of Pathology, Oregon Health Sciences University, Portland, Oregon.
authors.forename: Thomas G
authors.initials: TG
authors.lastname: DeLoughery
authors.affiliation: Georgetown University, Washington, District of Columbia and Private practice, Baltimore, Maryland.
authors.forename: Michael
authors.initials: M
authors.lastname: Auerbach
mesh_terms: D000367:Age Factors; D000465:Algorithms; D000707:Anaphylaxis / Q000139:chemically induced* / Q000453:epidemiology; D002626:Chemistry, Pharmaceutical; D002985:Clinical Protocols; D003953:Diagnosis-Related Groups; D004155:Diphenhydramine / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D038801:International Classification of Diseases; D007505:Iron-Dextran Complex / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008970:Molecular Weight; D011292:Premedication; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D004155:Diphenhydramine; D007505:Iron-Dextran Complex